9.2 Primary Wholesale Distributors

The primary wholesale distributors are the giants of the U.S. pharmaceutical supply chain. Three companies dominate this layer: Cardinal Health, McKesson, and Cencora (the corporate name adopted after the rebrand of AmerisourceBergen). Together these three handle the large majority of prescription drug distribution in the United States. The exam will not require you to recite an exact market-share percentage — what matters is that you recognize these three names, know the role of a primary wholesaler, and understand that distribution is concentrated among them.

What a Primary Wholesaler Does

A wholesale distributor is a trading partner under DSCSA that takes title to (owns) the product and resells it. The primary wholesaler's core functions are:

• Buys from manufacturers — wholesalers purchase product at a negotiated acquisition cost and hold inventory in their own distribution centers.
• Aggregates and stores — a single wholesaler distribution center may carry tens of thousands of SKUs from hundreds of manufacturers, letting a pharmacy order one shipment instead of placing orders with each manufacturer.
• Sells to dispensers — pharmacies, hospitals, health systems, clinics, and long-term care pharmacies buy from the wholesaler. The wholesaler invoices the dispenser at a price above its acquisition cost; that spread is part of how the wholesaler earns.
• Operates authorized distribution networks — a manufacturer may designate certain wholesalers as authorized distributors of its products. Product moving through the authorized network is presumptively genuine; product that appears outside that network may be diverted and triggers suspect-product scrutiny.

The Big 3 — Know the Names

The AmerisourceBergen → Cencora rename is a classic exam trap: older materials still say "AmerisourceBergen," and you should recognize both names as the same entity. PTCB's outline names primary wholesale distributors as a category but does not name specific companies; secondary and specialty wholesalers (Section 9.3) are a different, smaller category.

Services Beyond Moving Boxes

Primary wholesalers earn more than a simple buy-low/sell-high spread. They provide a bundle of services that manufacturers and pharmacies both rely on:

• Order management and EDI — pharmacies place orders electronically; the wholesaler's system confirms availability, ships, and invoices.
• Data and analytics — wholesalers sell or provide demand data, purchasing reports, and market analytics to manufacturers and to pharmacy customers.
• Chargeback administration — when a wholesaler sells a product at a contract price (for example, a 340B or GPO contract price) that is below what the wholesaler paid the manufacturer, the manufacturer issues a chargeback crediting the wholesaler for the difference. The wholesaler administers the documentation that supports the chargeback.
• Rebate administration — manufacturers pay rebates based on volume or contract terms; the wholesaler or a contracted intermediary may process the rebate paperwork and pass the rebate to the eligible customer.
• Recall and shortage support — wholesalers help push recall notices downstream to pharmacies and help manage allocations during a manufacturer shortage.

Chargebacks — a Worked Example

WAC/AWP pricing mechanics and chargebacks are not named in PTCB's outline for this Suppliers domain, which focuses on entity roles rather than pricing formulas; the walk-through below is professional background on how a wholesaler stays whole under contract pricing. Suppose:

• A manufacturer's wholesale acquisition cost (WAC) to the wholesaler is $100 per unit.
• A GPO contract sets a price of $80 per unit for GPO-member pharmacies.
• The wholesaler sells one unit to a GPO-member pharmacy at $80.
• The wholesaler paid $100 but collected only $80, a $20 shortfall.
• The manufacturer issues a $20 chargeback to credit the wholesaler for the contract discount.

The net effect: the manufacturer effectively funds the contract discount, and the wholesaler is made whole. The pharmacy gets the contract price; the wholesaler is not left absorbing the discount.

Authorized Distribution and Diversion

A manufacturer designates which wholesalers are authorized to distribute its products. The authorized network is the manufacturer's control on the integrity of its distribution channel. Two consequences follow:

1. Product in the authorized network carries a presumption of legitimate sourcing — the trading partners on the T3 documents are the ones the manufacturer expects.
2. Product outside the authorized network (for example, a brand drug offered by an unfamiliar secondary wholesaler at a deep discount) raises a diversion concern. Under DSCSA, a trading partner that has reason to believe product is diverted or counterfeit must treat it as suspect product, investigate, and if confirmed illegitimate, quarantine and notify FDA.

This is why a technician receiving an unexpected offer for a brand product from an unknown source must not simply stock the product — the transaction must be verified.

DSCSA Obligations on Wholesale Distributors

A wholesale distributor of covered prescription products is an authorized trading partner under DSCSA and must:

• Pass transaction data downstream — when selling or transferring ownership, pass Transaction Information and Transaction Statement to the receiving trading partner (Transaction History has not been required since its November 27, 2023 statutory sunset).
• Verify product — respond to verification requests from trading partners and from FDA; support package-level verification of the product identifier.
• Not accept unverified product — only accept product from an authorized trading partner and only with the required transaction data; reject shipments that arrive without TI/TS paper (with limited exceptions such as returns).
• Investigate suspect product — if there is reason to believe product is suspect (counterfeit, diverted, stolen, intentionally adulterated, intended for fraud, or otherwise unfit), investigate, and if the product is illegitimate, quarantine it, not distribute it, and notify FDA and immediate trading partners.
• Maintain records — retain transaction information and transaction statement for a minimum of six years (the DSCSA recordkeeping period).

Manufacturer → Wholesaler → Pharmacy Flow

The diagram below shows the standard flow, with T3 data passed at each step and a chargeback flowing back from manufacturer to wholesaler when a contract price applies.